To read the full article sign up for free or sign in.
Sep. 2, 2026
Roche Holding AG filled a trispecific antibody-sized hole in its B-cell disease franchise by bringing in Simcere Zaiming Pharmaceutical Co. Ltd.’s SIM-0600, a preclinical CD79a/CD19/CD3-targeting trispecific T-cell engager (TCE), under a potential $1.53 billion license deal.
BioWorld Deals and M&A Cancer Immune Inflammatory Antibody Asia-Pacific Europe China U.S.